$101 Million is the total value of Velan Capital Investment Management LP's 24 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 58.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FEZ | New | SPDR INDEX SHS FDSput | $15,380,000 | – | 500,000 | +100.0% | 15.26% | – |
| LNTH | Sell | LANTHEUS HLDGS INC | $14,066,000 | -20.7% | 200,000 | -25.6% | 13.95% | -22.5% |
| IMCR | IMMUNOCORE HLDGS PLCads | $13,771,000 | +25.8% | 293,385 | 0.0% | 13.66% | +23.0% | |
| ADMA | Sell | ADMA BIOLOGICS INC | $12,804,000 | +6.5% | 5,269,155 | -13.2% | 12.70% | +4.1% |
| OPTN | Buy | OPTINOSE INC | $7,966,000 | +8.8% | 2,176,572 | +8.8% | 7.90% | +6.4% |
| TELA | Buy | TELA BIO INC | $6,357,000 | +82.0% | 746,087 | +49.7% | 6.30% | +78.0% |
| HCSG | Buy | HEALTHCARE SVCS GROUP INC | $4,836,000 | +60.6% | 400,000 | +131.2% | 4.80% | +57.0% |
| HZNP | Buy | HORIZON THERAPEUTICS PUB L | $4,260,000 | +1697.5% | 68,829 | +2219.8% | 4.22% | +1660.4% |
| QIPT | Buy | QUIPT HOME MEDICAL CORP | $3,336,000 | +139.0% | 800,000 | +164.8% | 3.31% | +133.7% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2,835,000 | +19.1% | 225,000 | 0.0% | 2.81% | +16.4% | |
| Sell | THE ONCOLOGY INSTITUTE INC | $2,541,000 | -16.3% | 548,841 | -8.5% | 2.52% | -18.2% | |
| JASPER THERAPEUTICS INC | $2,240,000 | -59.1% | 3,219,036 | 0.0% | 2.22% | -60.0% | ||
| ZYME | New | ZYMEWORKS INC | $1,445,000 | – | 234,902 | +100.0% | 1.43% | – |
| CSU | SONIDA SENIOR LIVING INC | $1,345,000 | -22.7% | 82,832 | 0.0% | 1.33% | -24.4% | |
| Buy | ALIMERA SCIENCES INC | $1,156,000 | +13.0% | 227,602 | +21.7% | 1.15% | +10.5% | |
| RZLT | REZOLUTE INC | $1,096,000 | -15.2% | 400,000 | 0.0% | 1.09% | -17.1% | |
| BLU | New | BELLUS HEALTH INC NEW | $1,056,000 | – | 100,000 | +100.0% | 1.05% | – |
| CFMS | CONFORMIS INC | $986,000 | -45.9% | 5,156,406 | 0.0% | 0.98% | -47.1% | |
| XENE | XENON PHARMACEUTICALS INC | $722,000 | +18.8% | 20,000 | 0.0% | 0.72% | +16.0% | |
| COLL | New | COLLEGIUM PHARMACEUTICAL INC | $640,000 | – | 39,957 | +100.0% | 0.64% | – |
| New | LUMIRADX LTD | $583,000 | – | 571,428 | +100.0% | 0.58% | – | |
| ASRT | New | ASSERTIO HOLDINGS INC | $533,000 | – | 234,766 | +100.0% | 0.53% | – |
| Sell | NYXOAH S A | $498,000 | -40.5% | 79,021 | -13.2% | 0.49% | -41.8% | |
| GKOS | New | GLAUKOS CORP | $367,000 | – | 6,896 | +100.0% | 0.36% | – |
| Exit | SOMALOGIC INC*w exp 08/31/202 | $0 | – | -2,060 | -100.0% | -0.00% | – | |
| GFORWS | Exit | GRAF ACQUISITION CORP IV*w exp 05/31/202 | $0 | – | -20,000 | -100.0% | -0.01% | – |
| Exit | SCIENCE 37 HOLDINGS INC | $0 | – | -219,510 | -100.0% | -0.45% | – | |
| RDUS | Exit | RADIUS HEALTH INCcall | $0 | – | -50,000 | -100.0% | -0.53% | – |
| Exit | CARIBOU BIOSCIENCES INC | $0 | – | -210,695 | -100.0% | -1.16% | – | |
| XBI | Exit | SPDR SER TRcall | $0 | – | -50,000 | -100.0% | -3.77% | – |
| RDUS | Exit | RADIUS HEALTH INC | $0 | – | -1,771,500 | -100.0% | -18.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LANTHEUS HLDGS INC | 8 | Q3 2023 | 18.0% |
| ADMA BIOLOGICS INC | 8 | Q3 2023 | 13.7% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 17.8% |
| TELA BIO INC | 8 | Q3 2023 | 7.6% |
| REZOLUTE INC | 8 | Q3 2023 | 1.3% |
| OPTINOSE INC | 7 | Q3 2023 | 7.9% |
| IMMUNOCORE HLDGS PLC | 6 | Q1 2023 | 13.7% |
| ALIMERA SCIENCES INC | 6 | Q3 2023 | 34.0% |
| QUIPT HOME MEDICAL CORP | 6 | Q3 2023 | 4.8% |
| SONIDA SENIOR LIVING INC | 6 | Q1 2023 | 2.5% |
View Velan Capital Investment Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-28 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-09 |
| SC 13D/A | 2024-02-09 |
| SC 13G/A | 2024-01-29 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-10-04 |
| 4 | 2023-08-17 |
| SC 13D/A | 2023-08-16 |
| 13F-HR | 2023-08-11 |
View Velan Capital Investment Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.